2 Results

Sort by: Published date Updated Date Title ID Descending Ascending

Markers Predictive of Therapeutic Response in B-cell Malignancies Application Test to detect NF-kB2 breaks to guide treatment with proteasome inhibitors and its use with other therapeutic agents. Key Benefits Improved the prediction model to determine which patients are more likely to respond to bortezomib treatment. Improved the efficacy of treatment for patients with multiple myeloma and lymphomas. Market... Published: 3/19/2024       Contributor(s): Leon Bernal-Mizrachi

NF-Kappa B Activity as a Predictor and Diagnostic for the Two Sub-Groups of Diffuse Large B Cell Lymphoma Application Diagnostic assay that classifies non-Hodgkin's lymphoma specifically diffuse large B cell lymphoma (DLBCL) into two groups, which respond differently to chemotherapy. Key Benefits Uses gene expression profiling for classification. Provides classification of sub-group for a better selection of more specific and effective treatments. Market... Published: 7/28/2023       Contributor(s): Leon Bernal-Mizrachi